Atreca will bring Kristine Ball onto its board of directors, as the biotech seeks to expand available expertise whilst progressing its first-in-class product candidate, ATRC-101.
The antibody is enrolling patients with multiple solid tumor cancers for a Phase Ib trial.
Ball arrives after previously holding the role of chief financial officer at Menlo Therapeutics, Relypsa, and KAI Pharmaceuticals.
Atreca called attention to the fundraising that had taken place under her leadership at Relypsa, where she helped in raising over $675m (€612m) and the company’s acquisition by Galenica.
John Orwin, CEO of Atreca, said, “Ball brings a wealth of expertise gained over her career in the life sciences industry, during which she established a track record of executing on effective financing and corporate development strategies to help build successful companies.”